ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS

Melissa Holdren, Ont Schier, Susan J. Bartlett, Louis Bessette, Gilles Boire, Glen Hazelwood, Carol Hitchon, Edward Keystone, Diane Tin, Carter Thorne, Vivian Bykerk, Canada

Background: Up to 80% of rheumatoid arthritis patients report clinically relevant fatigue. Fatigue is complex multi-factorial process that can result in adverse affects on patients’ physical and emotional well-being. Objectives: To examine the relationship between disease activity and fatigue over time in early rheumatoid arthritis (ERA).

Methods: Data were from patients with ERA (symptoms ≤ 12 months) enrolled in the Canadian Early Arthritis Cohort (CATCH). CATCH participants completed repeat clinical assessments, laboratory investigations and self-reported questionnaires including rating their fatigue over the past week using a 10-point numerical rating scale (NRS). Fatigue severity was defined as low (≤2); moderate (>2 but ≤5) and high (>5) based on published other RA studies. Bivariate relationships between disease activity measures and fatigue over 5 years of follow-up were estimated using the Pearson correlation coefficient. T-tests and repeated measures were used to compare differences in fatigue ratings in patient who did vs. did not achieve a low disease state (DAS28 <3.2) within 3-months of cohort entry.

Results: Of the 1864 patients included, 1640 (88%) met criteria for RA, 1342 (72%) were women and most had moderate-high baseline disease with a mean (SD) DAS28 of 4.9 (1.5). Fatigue was common with 19% reporting moderate and 59% severe fatigue at baseline. Fatigue was positively and strongly correlated with pain and patient global ratings (r 0.56-0.67, p<0.001), positively and moderately correlated with DAS28 (r 0.35-0.49, p=0.001), and positively but more weakly correlated with tender/swollen joint count, physician global assessment, ESR and CRP (r 0.10-0.39, p<0.01) throughout the first year of follow-up. Patients who reported low fatigue severity by three months continued to have significantly lower fatigue throughout follow-up compared to those with moderate or high fatigue (p<0.001). Patients who achieved DAS28 REM or LDA within 3-months of cohort entry had significantly lower mean fatigue compared to those with more active disease throughout 5 years of follow-up (p<0.001) (Figure 1).

Disclosure of Interests: Melissa Holdren: None declared, Ont Schier: None declared, Susan J. Bartlett Consultant for: Pfizer, UCB, Lilly, Novartis, Merck, Janssen, AbbVie, Louis Bessette: Research support from: Amgen, BMS, Janssen, Roche, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Consultant for: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Speakers bureau: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Grant/research support from: Investigator-initiated studies: Amgen, BMS, Eli Lilly, Merck, Novartis; Pfizer, Consultant for: Advisory boards: Amgen, BMS, Celgene, Eli Lilly, Pfizer, Speakers bureau: Merck, BMS, Pfizer, Glen Hazelwood: None declared, C Arol Hitchen Grant/research support from: From: Pfizer, UCB (unrelated studies), Edward Keystone Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Sanofi-Aventis, Consultant for: AbbVie, Amgen, AstaZeneeca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, H. F Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, UCB, Speakers bureau: Amgen, AbbVie, Bristol-Myers Squibb Canada, F Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme, UCB, Diane Tin: None declared, Carter Thorne Grant/research support from: Investigator-initiated studies: Amgen, Pfizer, RCTs; AbbVie, Celgene, CalReBodam, Novartis, Pfizer, Consultant for: Advisory board: AbbVie, Amgen, Celgene, Lilly, Medexus/Medac, Merck, Novartis, Pfizer, Sanofi, Consultant: AbbVie, Centocor, Janssen, Lilly, Medexus/Medac, Pfizer, Speakers bureau: Medexus/Medac, Vivian Bykerk Grant/research support from: Mallinckrodt, BMS, Crescendo Biosciences, Sanofi/Regeneron, Consultant for: Amgen, Pfizer, UCB, Sciphar, Sanofi/Genzyme/Regeneron, Janet Pope Consultant for: Eli Lilly and Company

References:
[2] Slobucikos screening (TBsc) 12 months prior to starting a new biologic agent, b) documentation of clinical disease activity index (CDAI) in n≥50% of encounters, c) appropriate pneumococcal vaccination. We then planned an intervention by placing index cards at computer stations to remind providers to check these measures. We collected data on these 3 variables prior to the intervention (December 2016 - July 2017) and 30+ days after (August 2017 - December 2017). We also compared these results by provider type (attendings and fellows). For statistical analysis we used Chi-Square test and SPSS 24.

DISCLOSURE OF INTERESTS
None.

RESULTS: Baseline data included 240 patients, analysis prior to the intervention included 86 patients, and after the intervention included 131 patients. CDAI documentation was improved from 72.1% to 100% (p<0.001), however when stratifying the analysis by provider type, this improvement was only significant in attendings (p=0.005) and not in fellows (p=0.43). Further analysis by including only the same fellows in both pre and post intervention moments (some fellows graduated) showed a significant difference in both attendings (p=0.005; fellows: p=0.024). In terms of TBsc, baseline data showed 73.1% compliance, however we already found a compliance of 100% prior to the intervention (Figure 2, p<0.002 when compared with baseline data). Finally, there was no difference in compliance at the 30 day follow-up.

Acknowledgement: On behalf of Canadian Early Arthritis Cohort (CATCH) Investigators.
Conclusion: Placing a card reminding providers to check 3 RA quality measures significantly improved CDAI documentation after 30 days of starting the intervention. The compliance with TBsc prior to starting a new biologic agent was 100% even before the intervention, which was better compared to baseline data, likely due to providers being aware there was a problem after initial data was collected. We did not find improvement in pneumococcal immunization rate, most likely because there are multifactorial components to motivating patients to get the vaccine. Our results suggest that interventions as simple as raising provider awareness to a problem such as TB screening, and an index card to remind people to document CDAI can be effective to improve QI measures in RA patients in underserved communities.

REFERENCES:

Disclosure of Interests: None declared

OP0317 ASSOCIATION OF PATIENT SATISFACTION WITH HEALTHCARE UTILIZATION, COST, AND QUALITY OF LIFE IN RHEUMATOID ARTHRITIS

Nazim Khan1,2, Fawad Aslam1, Wais Atzal1, Chenghui Li1,1, University of Arkansas for Medical Sciences, Little Rock, United States of America; 2Central Arkansas Veterans Healthcare System, Little Rock, United States of America; 3Mayo Clinic, Phoenix, United States of America

Background: Patient satisfaction and experience with care is being used as a surrogate marker of quality and value of healthcare delivery. No study has evaluated the association of patient satisfaction with healthcare utilization and cost, and quality of life in RA patients.

Objectives: To examine the association of RA patient satisfaction with healthcare utilization and cost, and quality of life.

Methods: 2010-2015 longitudinal files from the Medical Expenditure Panel Survey (MEPS), a nationally representative survey of the US civilian non-institutionalized population were used to identify patients with self-reported RA diagnosis. MEPS has overlapping panel design with participants interviewed up to 5 rounds over a 2- year period. In rounds 2 and 4, patient satisfaction is assessed by the four items about physician interaction – listened carefully, explained things well, showed respect, and spent enough time; and one item for overall satisfaction with quality of care received. A patient satisfaction score was constructed from standardized composite score of these items, and classified as most satisfied (patient satisfaction quartile 4) and least satisfied (patient satisfaction quartiles 1-3). The outcome measures were assessed in year 2: healthcare utilization (any emergency department visit, any inpatient stay, number of visits to office-based providers, outpatient department, and prescription drugs); total healthcare expenditures (measured in 2015 dollars), and quality of life (QoL, measure using 12-item Short Form healthy survey (SF-12)). Two statistical approaches were used: a standard logistic regression comparing most satisfied with least satisfied, and propensity score matching. Propensity scores were estimated using a logistic regression to model most satisfied quartile (vs. lower) as a function of covariates (satisfaction score in year 1 were matched 1 to 1 without replacement using a greedy matching algorithm. After matching, means of outcomes in year 2 were compared among matched pairs. Standard errors were estimated using bootstrapping method with 200 repetitions. Covariates included socio-demographic measures, health behaviors, health status (Charlson Comorbidity Index, general health, activity limitation, and pain affecting activities); RA measures (DMARDs, corticosteroids, and analgesics use); and the Year 1 outcome measures (utilization, total expenditure, QoL).

Results: 568 patients had a self-reported RA diagnosis. 1025 (65.4%) patients were analyzed (326 patients excluded for missing satisfaction response; 201 patients for missing information on other study variables; and 16 for not having data in all 5 rounds). The results using the propensity score matching approach are presented in the Table (202 most satisfied matched to 202 least satisfied patients). There were no differences in the healthcare utilization, cost and QoL among the two groups. Logistic regression approach yielded similar results.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Most satisfied, Q4</th>
<th>Less satisfied, Q1-Q3</th>
<th>Difference</th>
<th>Bootstrapped SE (p&lt;0.05)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total expenditure, $</td>
<td>13452</td>
<td>14095</td>
<td>-643</td>
<td>2607</td>
<td>0.633</td>
</tr>
<tr>
<td>Number of Office Visits</td>
<td>12.34</td>
<td>12.73</td>
<td>0.39</td>
<td>1.55</td>
<td>0.741</td>
</tr>
<tr>
<td>Number of Outpatient Visits</td>
<td>1.06</td>
<td>1.34</td>
<td>-0.28</td>
<td>0.95</td>
<td>0.272</td>
</tr>
<tr>
<td>Number of Inpatient Visits</td>
<td>0.23</td>
<td>0.34</td>
<td>-0.09</td>
<td>0.085</td>
<td>0.367</td>
</tr>
<tr>
<td>Number of ER Visits</td>
<td>0.460</td>
<td>0.525</td>
<td>-0.064</td>
<td>0.107</td>
<td>0.547</td>
</tr>
<tr>
<td>Number of Prescriptions</td>
<td>48.916</td>
<td>53.465</td>
<td>-4.55</td>
<td>4.351</td>
<td>0.561</td>
</tr>
<tr>
<td>QoL - Mental health summary scores</td>
<td>47.557</td>
<td>47.186</td>
<td>0.371</td>
<td>1.136</td>
<td>0.379</td>
</tr>
<tr>
<td>QoL - Physical health summary scores</td>
<td>36.526</td>
<td>34.840</td>
<td>1.686</td>
<td>0.969</td>
<td>0.082</td>
</tr>
</tbody>
</table>

Conclusion: Patient satisfaction score of RA patients was not associated with healthcare utilization and cost, and quality of life measures.

REFERENCE:

Disclosure of Interests: None declared

FRIDAY, 14 JUNE 2019

Teenage look in the mirror (sexuality and body image meeting health care)

OP0318-HPR IS PSYCHOLOGICAL SUPPORT REACHING THOSE IN MOST NEED? A SURVEY OF PEOPLE WITH RHEUMATOID ARTHRITIS AND ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS:

Hayley McBean1, Matthew Bezzant2, Alisa Bosworth3, 1City, University of London, London, United Kingdom; 2National Rheumatoid Arthritis Society (NRAS), Maidenhead, United Kingdom

Background: Rheumatoid arthritis (RA) and adult juvenile idiopathic arthritis (AJA) is associated with a significant impact on psychological well-being.1,2 UK guidelines for the management of RA3,4 state that psychological interventions should be offered to people with RA to help them adjust to living with their condition and manage their psychological well-being. Three in four rheumatology units in the UK however, rate their overall provision of psychological support as inadequate.5

Objectives: To establish levels of anxiety and depression in people with RA or AJA and how this relates to the prevalence of diagnosed mood disorders and receipt of psychological support.

Methods: The 2018 National Rheumatoid Arthritis Society (NRAS) ‘Emotional Health and Well-being Matters’ survey was designed by patients and researchers. This included a questionnaire designed to capture self-reported comorbidities, receipt of psychosocial support and the Hospital Anxiety and Depression Scale (HADS).6 Participants were recruited by NRAS via their social media platforms, membership and non-membership lists and in newsletters and forum. The survey was open from May-July 2018. Recruitment was focused on those diagnosed with RA or AJA aged 18 years and over and living in the UK.

Results: A total of 1565 people with RA and 55 AJA completed the survey. Although mean scores on the HADS were within the normal range in both populations, over 25% of the samples were experiencing clinical levels of anxiety or depression. Over half of those reporting clinical levels of anxiety or depression had never received a formal diagnosis. Most concerning however, was that 1 in 2